News

"Make America Healthy Again” has taken a jab at psychiatry.

Antipsychiatry’s animus toward psychiatric medication has both ancient and modern parallels.

Frontal lobe syndrome can present with a range of perseverative, disinhibited, overactive behaviors that do not meet traditional dementia/neurocognitive disorder criteria. Learn more here.

Massive federal layoffs: how will this impact mental health?

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

Who is the ‘bad guy’ of health care? Insurance? Clinicians? Or something else?

Honoring Lisa Hunter Romanelli, PhD, the Elevate Prize will help scale REACH's work in addressing the children’s mental health crisis.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

In the psychiatric care continuum, insurance companies encourage a broader conversation about what constitutes best treatment practices.

Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis.

Judith S. Beck, PhD, and Janeé M. Steele, PhD, engage in a conversation about how clinicians from all backgrounds can address issues of race in session and also empower Black patients with a sense of personal pride in their identities.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

What are the current, emerging mental health concerns?

Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

Let's reflect on managed care as we celebrate the 40th anniversary of Psychiatric Times.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Today, let’s be loving to the environment and each other.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Check out these 7 insights and perspectives on recognizing and treating PTSD.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

"It is the winter of chest pain and snow, all the drunks smashed through the ER doors..."

Is physician burnout slowing down?

Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.